Regulations

(Image: Getty/Klebercordeiro)

Lilly expands migraine offerings after FDA approval

By Ben Hargreaves

US FDA gives marketing authorization to Lilly’s oral medication for the acute treatment of migraines in adult patients, adding to its Emgality approval almost exactly a year ago.

(Image: Getty/Kevron2001)

FDA aims to speed naloxone generics to market

By Ben Hargreaves

US FDA follows up the first generic approval of naloxone nasal spray by encouraging companies to apply with generic applications amid the North American opioid crisis.

(Image: Getty/NicoElNino)

Ranitidine recalls sweep globe

By Ben Hargreaves

US, Canadian, South Korean, and Indian authorities recommend the recall of certain ranitidine medicines due to cancer-causing impurity.

(Image: Getty/Zozulya)

Torrent expands recall of losartan products, again

By Ben Hargreaves

Torrent announces that it will recall batches of losartan tablets for the sixth time, after the detection of NMBA exceeding acceptable daily intake levels in latest recall.

(Image: Getty/HS3RUS)

POLL

How invested is pharma in sustainability?

By Ben Hargreaves

As a day of climate strikes unfolds across the world, we ask how far pharma is engaged on the issue, as well as noting recent innovations that suggest companies are looking at what can be done.